Literature DB >> 26464284

Inhibition and deficiency of the immunoproteasome subunit LMP7 attenuates LCMV-induced meningitis.

Sarah Mundt1,2, Britta Engelhardt3, Christopher J Kirk4, Marcus Groettrup1,5, Michael Basler1,5.   

Abstract

In addition to antigen processing, immunoproteasomes were recently shown to exert functions influencing cytokine production by monocytes and T cells, T-helper cell differentiation, and T-cell survival. Moreover, selective inhibition of the immunoproteasome subunit LMP7 ameliorated symptoms of autoimmune diseases including CD4(+) T-cell mediated EAE. In this study, we show that LMP7 also plays a crucial role in the pathogenesis of lymphocytic choriomeningitis virus (LCMV)-induced meningitis mediated by CTLs. Mice lacking functional LMP7 display delayed and reduced clinical signs of disease accompanied by a strongly decreased inflammatory infiltration into the brain. Interestingly, we found that selective inhibition and genetic deficiency of LMP7 affect the pathogenesis of LCMV-induced meningitis in a distinct manner. Our findings support the important role of LMP7 in inflammatory disorders and suggest immunoproteasome inhibition as a novel strategy against inflammation-induced neuropathology in the CNS.
© 2015 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  CNS inflammation; Cytotoxic T cells; Immunoproteasome; LMP7; Lymphocytic choriomeningitis virus

Mesh:

Substances:

Year:  2015        PMID: 26464284     DOI: 10.1002/eji.201545578

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  16 in total

1.  Amelioration of autoimmunity with an inhibitor selectively targeting all active centres of the immunoproteasome.

Authors:  Michael Basler; Elmer Maurits; Gerjan de Bruin; Julia Koerner; Herman S Overkleeft; Marcus Groettrup
Journal:  Br J Pharmacol       Date:  2017-11-29       Impact factor: 8.739

2.  Co-inhibition of immunoproteasome subunits LMP2 and LMP7 is required to block autoimmunity.

Authors:  Michael Basler; Michelle M Lindstrom; Jacob J LaStant; J Michael Bradshaw; Timothy D Owens; Christian Schmidt; Elmer Maurits; Christopher Tsu; Herman S Overkleeft; Christopher J Kirk; Claire L Langrish; Marcus Groettrup
Journal:  EMBO Rep       Date:  2018-10-02       Impact factor: 8.807

3.  Therapeutic Potential of Immunoproteasome Inhibition in Duchenne Muscular Dystrophy.

Authors:  Andrea Farini; Clementina Sitzia; Barbara Cassani; Letizia Cassinelli; Rosita Rigoni; Federica Colleoni; Nicola Fusco; Stefano Gatti; Pamela Bella; Chiara Villa; Filomena Napolitano; Rita Maiavacca; Silvano Bosari; Anna Villa; Yvan Torrente
Journal:  Mol Ther       Date:  2016-08-10       Impact factor: 11.454

Review 4.  On the role of the immunoproteasome in transplant rejection.

Authors:  Michael Basler; Jun Li; Marcus Groettrup
Journal:  Immunogenetics       Date:  2018-09-15       Impact factor: 2.846

5.  Chronic Toxoplasma gondii infection enhances β-amyloid phagocytosis and clearance by recruited monocytes.

Authors:  Luisa Möhle; Nicole Israel; Kristin Paarmann; Markus Krohn; Sabine Pietkiewicz; Andreas Müller; Inna N Lavrik; Jeffrey S Buguliskis; Björn H Schott; Dirk Schlüter; Eckart D Gundelfinger; Dirk Montag; Ulrike Seifert; Jens Pahnke; Ildiko Rita Dunay
Journal:  Acta Neuropathol Commun       Date:  2016-03-16       Impact factor: 7.801

6.  The immunoproteasome-specific inhibitor ONX 0914 reverses susceptibility to acute viral myocarditis.

Authors:  Nadine Althof; Carl Christoph Goetzke; Meike Kespohl; Karolin Voss; Arnd Heuser; Sandra Pinkert; Ziya Kaya; Karin Klingel; Antje Beling
Journal:  EMBO Mol Med       Date:  2018-02       Impact factor: 12.137

7.  ONX 0914 Lacks Selectivity for the Cardiac Immunoproteasome in CoxsackievirusB3 Myocarditis of NMRI Mice and Promotes Virus-Mediated Tissue Damage.

Authors:  Hannah Louise Neumaier; Shelly Harel; Karin Klingel; Ziya Kaya; Arnd Heuser; Meike Kespohl; Antje Beling
Journal:  Cells       Date:  2020-04-28       Impact factor: 6.600

8.  Immunoproteasome Inhibition Impairs T and B Cell Activation by Restraining ERK Signaling and Proteostasis.

Authors:  Christian Schmidt; Thilo Berger; Marcus Groettrup; Michael Basler
Journal:  Front Immunol       Date:  2018-10-26       Impact factor: 7.561

9.  Noncytotoxic Inhibition of the Immunoproteasome Regulates Human Immune Cells In Vitro and Suppresses Cutaneous Inflammation in the Mouse.

Authors:  Marie Dominique Ah Kioon; Michael Pierides; Tania Pannellini; Gang Lin; Carl F Nathan; Franck J Barrat
Journal:  J Immunol       Date:  2021-03-05       Impact factor: 5.422

Review 10.  Neuroinflammation and Infection: Molecular Mechanisms Associated with Dysfunction of Neurovascular Unit.

Authors:  Abolghasem Tohidpour; Andrey V Morgun; Elizaveta B Boitsova; Natalia A Malinovskaya; Galina P Martynova; Elena D Khilazheva; Natalia V Kopylevich; Galina E Gertsog; Alla B Salmina
Journal:  Front Cell Infect Microbiol       Date:  2017-06-20       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.